EGF Receptor-Targeting Cancer Therapy Using CD47-Engineered Cell-Derived Nanoplatforms

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Clinical application of nanoparticle therapeutics is hindered by phagocytic cell uptake and off-target toxicity.
• Developing strategies to evade immune surveillance and improve tumor targeting is crucial for effective cancer treatment.

Purpose of the Study:

• To engineer CD47-expressing nanoparticles (CDNs) for enhanced anti-cancer drug delivery.
• To evaluate the efficacy of CDNs functionalized with anti-EGFR antibodies for targeted cancer therapy.

Main Methods:

• CDNs were prepared from CD47-transfected human embryonic kidney cells.
• Doxorubicin (DOX) was loaded into CDNs, and anti-EGFR antibodies were conjugated for targeted delivery.
• In vitro and in vivo studies were conducted to assess cellular uptake, tumor targeting, and anti-cancer efficacy.

Main Results:

• Synthesized CD47+iCDNs-DOX demonstrated stable structures and reduced uptake by macrophages.
• Targeted CDNs selectively recognized EGFR-positive cancer cells and accumulated in tumor xenografts.
• iCDNs-DOX significantly suppressed tumor growth in mice, indicating enhanced drug delivery.

Conclusions:

• Functionalizing cell membrane-derived nanocarriers with CD47 and tumor-targeting antibodies can overcome immune evasion and improve drug delivery.
• This approach shows promise for facilitating the clinical application of biocompatible nanocarriers in cancer therapy.